Previous 10 | Next 10 |
SAN CARLOS, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (...
There is no such thing as a value trap. There are investing mistakes. - Mohnish Pabrai In my experience, I noticed that the bioscience market is the field with the most lucrative returns. Yet, there is a tendency to chase a high-flying stock without adequately studying its fundamentals. Th...
"Long books, when read, are usually overpraised, because the reader wishes to convince others and himself that he has not wasted his time .” ― E.M. Forster, Aspects of the Novel Iovance Biotherapeutics ( IOVA ) is one of several small biotech holdings making big moves this...
IOVA stock is on fire in Thursday’s session after Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced positive results for its LN 145, an advanced cervical cancer drug. California-based biotechnology company, Iovance Biotherapeutics, has been one of the most interesting and innov...
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D...
Iovance Biotherapeutics (NASDAQ: IOVA ) +36% on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more ...
Iovance Biotherapeutics (NASDAQ: IOVA ) is up 28% premarket on light volume in reaction to new interim data from clinical trials evaluating its tumor-infiltrating lymphocyte (TIL) candidates. The data will be presented at ASCO in Chicago. More news on: Iovance Biotherapeutics...
Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileucel following failure of checkpoint inhibitors had objective response rate of 38 percent First patient dosed in I...
Iovance Biotherapeutics, Inc. (IOVA) Q1 2019 Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Tim Morris – Chief Financial Officer Kelly DiTrapani – Vice President-Medical Affairs Michael Swartzburg – Vice President-Finance Conference C...
- First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 - - New interim data from melanoma Cohort 2 and cervical cancer studies to be presented in June at the 2019 American Society of Clinical Oncology (ASCO) meeti...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly fina...
2024-05-10 14:03:28 ET Iovance Biotherapeutics (NASDAQ: IOVA) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk response to the news, ho...